What the New Study Found
A recent observational study published in The Lancet Regional Health - Europe has drawn significant attention. Researchers analyzed health records from over 80,000 people with type 2 diabetes in Italy and found that those who stopped taking GLP-1 receptor
agonists (GLP-1 RAs) had about double the risk of a heart attack, stroke, or death compared to those who continued the medication. Specifically, the rate of these adverse events was 3.94 per 100 person-years in the group that stopped, versus 1.96 in the group that continued. The data, collected between 2004 and 2024, showed that over 60% of patients had discontinued their GLP-1 medication by their last visit. The link appeared even stronger in patients with a BMI of 30 or higher. While these numbers sound alarming, the study's authors and other experts are urging careful interpretation.
The Crucial 'Causation' Caveat
The most important part of this study is what it doesn't say. Because it was an observational study, it can only show an association or a correlation, not a direct cause-and-effect relationship. The researchers themselves emphasized that they could not establish that stopping the medication directly causes these increased risks. There could be other factors at play. For instance, some people may have stopped the medication because they were already experiencing other health problems or serious illness, which would independently increase their risk of a cardiovascular event. The study did not have information on why patients stopped treatment, which is a major limitation. Discontinuation, in this context, might simply be a marker for a patient population with higher underlying risk, rather than the trigger for that risk.
Why Do People Stop Taking GLP-1s?
Understanding why discontinuation happens is key to interpreting the study. Real-world data shows that stopping these drugs is incredibly common, with some estimates suggesting discontinuation rates as high as 81% within the first year. The reasons are varied. Gastrointestinal side effects, such as nausea and digestive issues, are a primary driver for people quitting the medication. Cost and insurance coverage are also significant barriers for many. Additionally, some patients may stop due to a perceived lack of effectiveness, supply shortages, or simply the inconvenience of a regular injection. This highlights that the group of people who stop taking GLP-1s is not random; they often face specific challenges that may also be linked to their overall health.
Reversal of Benefits is a Known Factor
While the new study can't prove causation, we do know from previous research that the benefits of GLP-1 drugs tend to reverse upon discontinuation. These medications are intended for long-term management of chronic conditions like obesity and diabetes. Multiple trials, including the well-known STEP trials, have shown that when people stop taking drugs like semaglutide, they regain a significant portion of the weight they lost—often about two-thirds within a year. Along with weight regain, improvements in blood sugar, blood pressure, and cholesterol levels also tend to revert toward baseline. This 'metabolic whiplash' is a known consequence of stopping treatment and likely contributes to the loss of cardiovascular protection that the drugs provide. Therefore, while stopping the drug might not directly 'cause' a heart attack, losing its protective effects re-exposes a patient to their underlying risks.
What This Means for Patients
The key takeaway is not that stopping GLP-1s is definitively dangerous, but that these are chronic medications for chronic diseases, and continuous treatment is necessary to maintain their benefits. The findings reinforce the importance of having a conversation with your healthcare provider before making any changes to your medication regimen. If you are struggling with side effects, cost, or other issues, your doctor may be able to help by adjusting the dose, suggesting management strategies for side effects, or exploring alternative treatments. Stopping abruptly without a plan means losing the metabolic and cardiovascular benefits you've gained. This study, despite its limitations, serves as an important reminder that managing a chronic condition is a long-term journey that requires ongoing partnership between patient and doctor.
















